Press release written by Fedor Zurabov at MicroMir.
Research and Production Center “MicroMir” (RPC “Micromir”) and the Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology (FRCC ICMR) described the concept of selecting bacteriophages not for individual patients but for the entire spectrum of bacteria circulating in the intensive care unit (ICU).
WHO estimates that the existence of antibiotic-resistant strains of bacteria is a global public health threat, as it causes millions of deaths each year. As more drugs become ineffective, interest in bacteriophage therapy is growing worldwide. However, there is a problem: no new commercially available phage therapeutics have been developed in the last two decades, as it is difficult to register them under current legislation in many countries.
Adaptive Phage therapy for ICU patients
An alternative way to legalize phages for clinical use has been proposed by scientists from the RPC “Micromir” and the FRCC ICMR, called “Adaptive phage therapy”. Such therapy involves selecting bacteriophages not for individual patients, but for the entire spectrum of bacteria circulating in the ICU, and constant monitoring of their efficacy.
The study details three new cases of phage cocktail administration in ICU patients following the described protocol. They received the preparation in the form of inhalation for 28 days without the use of antibiotics.
Key observations include:
- No observed side effects.
- All patients showed elimination of multi-drug-resistant microorganisms from bronchoalveolar lavage.
- Computer tomography data indicated improvement in lung condition.
- Inflammatory markers, such as C-reactive protein (CRP) and procalcitonin, decreased.
The results suggest that adaptive phage therapy can be applied in hospitals to reduce antibiotic use while maintaining their efficacy.
Fedor Zurabov, Marina Petrova, Alexander Zurabov, Marina Gurkova, Petr Polyakov, Dmitriy Cheboksarov, Ekaterina Chernevskaya, Mikhail Yuryev, Valentina Popova, Artem Kuzovlev, Alexey Yakovlev & Andrey Grechko. Published in Antibiotics 2023 | DOI: 10.3390/antibiotics12121734
Research and production center “MicroMir” was founded in 2011. They stand for an eco-friendly approach to the human microbiome. MicroMir’s production center was built and operates in accordance with GMP regulations.
Currently, the company’s product portfolio includes 4 preparations with bacteriophages for humans, 1 product with bacteriophages for prevention and treatment of endometritis of bacterial etiopathogenesis in cows is registered as a drug for veterinary use in Russia, 1 preparation with bacteriophages for prevention of bacterial diseases in poultry farming is registered in Hungary. Jointly with Iskra, a cosmetic product with bacteriophages for problem skin has been registered and supplied to Japan. The company continues to develop preparations with bacteriophages for humans and livestock and actively cooperates with clinical institutions and agricultural producers.